Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis

Not Applicable

Recruiting

• Conditions: Neurogenic Bowel (Disorder); Fecal Incontinence; Fecal Constipation; Multiple Sclerosis
• Interventions: Device: Navina Smart; Other: Standard Bowel Care

• Registration Number: NCT04707976
• Lead Sponsor: Wellspect HealthCare

Brief Summary

A randomized, superiority, controlled, interventional, prospective, multicentre, post-market study of TAI with Navina™ Smart versus Standard Bowel Care performed in a population of 92 subjects suffering from Multiple Sclerosis and confirmed Neurogenic Bowel Dysfunction. The study is expected to last for a total of 8 weeks per subject with two scheduled site visits.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-10-22
• Study Start: 2020-12-01
• Study First Submitted QC: 2021-01-11
• Study First Posted: 2021-01-13
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-10
• Last Update Posted: 2024-07-11
• Primary Completion: 2024-12
• Study Completion: 2025-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 92

Inclusion Criteria

For inclusion in the study, subjects must fulfil all of the following criteria:

1. Provision of informed consent.
2. Female or male aged 18 years or above.
3. Established diagnosis of MS according to McDonald criteria.
4. Patients with bowel symptoms post-dating and related to a diagnosis of MS.
5. Patients suffering from NBD symptoms defined by Wexner feacal incontinence score ≥10 and/or Cleveland Clinic constipation score ≥10 confirmed at Baseline.
6. Only TAI treatment naïve patient (not having previously used any particular TAI system).
7. Judged eligible for TAI as per standardized treatment pathway.
8. Able to read, write and understand information given to them regarding the study.

Exclusion Criteria

Any of the following is regarded as a criterion for exclusion from the study:

1. Any confirmed or suspected diagnosis of anal or colorectal stenosis, active inflammatory bowel disease, acute diverticulitis, severe diverticulosis, colorectal cancer, ischemic colitis, history of life-threatening autonomic dysreflexia, bleeding disorders, unspecified peri-anal conditions.

2. Untreated rectal impaction.

3. Other significant neurological diseases (defined as all neurological diseases except for minor functional neurological syndromes or non-MS related neuro complications).

4. Opioid consumption ≤24 hours prior enrolment.

5. Previous colorectal surgery (including haemorrhoidectomy and fistulotomy), sphincter injury, perianal sepsis, rectal prolapse.

6. Performed endoscopic polypectomy within 4 weeks prior enrolment.

7. Ongoing, confirmed pregnancy or lactation.

8. Any neuromodulation that can affect the pelvic organ function.

9. Ongoing, symptomatic Urinary Tract Infection (UTI) at enrolment (defined as a positive urine culture of ≥10^3 CFU/ml of ≥1 bacterial species and presence of symptoms or signs compatible with UTI with no other identified source of infection).*

10. Current treatment with anticoagulants (exception acetylsalicylic acid or clopidogrel).

11. Current treatment with long-term systemic steroid medication (exception inhalation agents and/or local topical treatment).

12. Current treatment of prokinetics.

13. Involvement in the planning and conduct of the study (applies to both Wellspect HealthCare and site personnel).

14. Previous enrolment in the present study.

15. Simultaneous participation in another clinical study that may interfere with the present study as judged by the investigator.

16. Expected severe non-compliance to protocol as judged by the investigator.

17. Any other condition, as judged by the investigator, which might make follow-up or investigations inappropriate.

18. Any patient that according to the Declaration of Helsinki is unsuitable for enrolment.

19. Agranulocytosis (<0.5 10^9 / L) [Only applicable for Switzerland].

    • If symptoms and signs compatible with UTI is present but no urine culture test has been performed yet, a test should be performed, and the result received prior evaluating if the subject is eligible for study participation. After successful and completed treatment of a UTI, the subject may be rescheduled for Visit 1 in order to re-evaluate study participation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Navina Smart	Navina Smart	An electronic medical device to perform transanal irrigation. Treatment period 8 weeks.
Standard Bowel Care	Standard Bowel Care	Supportive bowel care without using irrigation.

Primary Outcome Measures

Name	Time	Method
Change in fecal incontinence score.	8 weeks	Relative change in Wexner fecal incontinence score at 8 weeks relative to Baseline in the TAI arm, compared to the SBC arm.
Change in fecal constipation score	8 weeks.	Relative change in Cleveland Clinic constipation score at 8 weeks relative to Baseline in the TAI arm, compared to the SBC arm.

Secondary Outcome Measures

Name	Time	Method
Change in perception of impact of bowel symptoms on QoL	8 weeks	Relative change of impact on bowel-related QoL between baseline and 8 weeks in the TAI arm, compared to the SBC arm, as measured by a single question.
Change in bladder specific QoL	8 weeks	Absolute and relative change in SF-Qualiveen questionnaire between Baseline and 8 weeks in the TAI arm, compared to the SBC arm.
Navina Smart: Correlation APP/irrigation parameters	8 weeks.	Balloon inflation correlation with Anorectal Physiology Parameters (APPs) after 8 weeks in subjects who perform the anorectal physiology test, treated with Navina Smart, and using the Navina Smart App.
Change in NBD symptoms	4 weeks and 8 weeks	Absolute and relative change in NBD score between Baseline and 4 and 8 weeks in the Navina arm, compared to the SBC arm.
Study therapy adherence	4 weeks and 8 weeks	Number of subjects using Navina Smart or SBC at 4 weeks and 8 weeks treatment, as measured by a single question.
Frequency of UTI	8 weeks	Number of UTIs requiring antibiotic treatment 8 weeks prior study start (Baseline) and at 8 weeks after treatment (Visit 2), as reported by subject.
Efficacy of TAI with Navina Smart vs. SBC	8 weeks	Relative change in Cleveland Clinic constipation score at 4 weeks relative to Baseline in the TAI arm, compared to the SBC arm
Navina Smart: Correlation anorectal APP/irrigation parameters between responders/non-responders	8 weeks	Correlation between Anorectal Physiology Parameters (APPs), irrigations parameters(volume/frequency of irrigation and balloon inflation) and outcome of TAI treatment between responders versus non-responders in subjects who perform the anorectal physiology test, treated with Navina Smart, and using the Navina Smart App for 8 weeks. A responder is defined as an improvement equal to the 25th percentile of the change in Cleveland Clinic Constipation score when using TAI with Navina Smart.

Trial Locations

Locations (9)

AOU Careggi; 🇮🇹 Florence, Tuscany, Italy

AISM Liguria Rehabilitation Centre; 🇮🇹 Genova, Liguria, Italy

Azienda Ospedaliero-Universitaria of Ferrara; 🇮🇹 Ferrara, Cona, Italy

Aarhus University Hospital; 🇩🇰 Aarhus, Denmark

Hospital Tenon Service de Neuro-urologie et d'Explorations Périnéales; 🇫🇷 Paris, France

Centre Hospitalier Universitaire Vaudois (CHUV); 🇨🇭 Lausanne, Switzerland

Azienda Ospedaliero Universitaria Consorziale Policlinico con sede in Bari; 🇮🇹 Bari, Italy

La Fé University Hospital; 🇪🇸 Valencia, Spain

University College London Hospital; 🇬🇧 London, United Kingdom